יחס שווי שוק לשווי בספרים OKYO Pharma Ltd (OKYO)

OKYO Pharma Limited is based at a British research center, while drug synthesis is delegated to third-party CDMO facilities. The firm's environmental strategy is minimal, limited to green office standards. The available price action vector is recorded at 6.22. The business relies on the development of treatments for dry eye, where patent protection will ensure pricing power until the rights expire.

For OKYO Pharma Limited, which is creating a closed-loop cycle for the therapy of ocular pathologies, the market value-to-book value ratio on GURU.Markets reflects the market valuation of its intellectual capital. This metric compares the current market capitalization with the issuer's net asset value. The calculation determines the premium investors are willing to pay for unique lipid developments. The trend line demonstrates the balance between speculative demand and the actual value of the business. The stability of this indicator confirms the fundamental resilience of the company's financial base.